

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: H. Lundbeck A/SApplication No./Patent No.: 7,135,181 Filed/Issue Date: 11/14/2006Entitled: **METHOD FOR DOWN-REGULATION OF AMYLOID**H. Lundbeck A/S, a corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest  
(The extent (by percentage) of its ownership interest is \_\_\_\_\_%)

in the patent application/patent identified above by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

Martin Roland Jensen, Peter Birk

1. From: Rasmussen, Klaus Gregorius Nielsen To: Pharmexa A/S  
The document was recorded in the United States Patent and Trademark Office at  
Reel 012952, Frame 0677, or for which a copy thereof is attached.

2. From: Pharmexa A/S To: H. Lundbeck A/S  
The document was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.


3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.



Signature

LARS BO KSERNUMGAARD

Printed or Typed Name

HEAD OF DEPARTMENT

Title

11 NOVEMBER 2008

Date

+45 3643 4118

Telephone Number

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

## ASSIGNMENT

WHEREAS, PHARMEXA A/S, having its office at Kogle Alle 6, DK-2970 Horsholm, Denmark, hereinafter referred to as ASSIGNOR, holds the complete right, title and interest by means of assignment in the following:

1. U.S. Patent No. 7,135,181, issued November 14, 2006, entitled "Method for Down-Regulation Of Amyloid", as recorded in the U.S. Patent and Trademark Office on June 3, 2002 at Reel/Frame 012952/0677;
2. U.S. Patent Application No. 10/204,362, filed August 16, 2002, entitled "Novel Method for Down-Regulation of Amyloid", as recorded in the U.S. Patent and Trademark Office on August 16, 2002 at Reel/Frame 013321/0094;
3. U.S. Patent Application No. 11/537,566, filed September 29, 2006, entitled "Novel Method for Down-Regulation of Amyloid", as recorded in the U.S. Patent and Trademark Office on September 10, 2008 at Reel/Frame 021509/0992; and
4. U.S. Patent Application No. 12/108,478, filed April 23, 2008, entitled "Novel Method For Down-Regulation Of Amyloid", as recorded in the U.S. Patent and Trademark Office on September 10, 2008 at Reel/Frame 021510/0016.

WHEREAS, H. LUNDBECK A/S, located at Ottiliavej 9, DK-2500 Valby, Copenhagen, Denmark, hereinafter referred to as ASSIGNEE, is desirous of obtaining the entire right, title and interest in, to and under the improvements and the application;


NOW, THEREFORE, in consideration of the sum of One Dollar (\$1.00) to ASSIGNOR in hand paid, and other good and valuable consideration, the receipt of which is hereby acknowledged, the ASSIGNOR has sold, assigned, transferred and set over, and by these presents does hereby sell, assign, transfer and set over, unto the ASSIGNEE, its successors, legal representatives and assigns, the entire right, title and interest in, to and under the Patents, all improvements therein, and the application thereof and all divisions, renewals and continuations thereof, and all Letters Patent of the United States which may be or have been granted thereon and all reissues and extensions thereof, and all applications for Letters Patent which have been or may hereafter be filed for the improvements in any country or countries, including or foreign to the United States, and all Letters Patent which may be or have been granted for the improvements in any country or countries, including or foreign to the United States and all extensions, renewals and reissues thereof; and ASSIGNOR hereby authorizes and requests the Commissioner of Patents of the United States, and any Official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue all Letters Patent for the improvements to the ASSIGNEE, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

ASSIGNOR hereby covenant that ASSIGNOR has full right to convey the entire interest herein assigned, and that ASSIGNOR has not executed, and will not execute, any agreement in conflict herewith.


ASSIGNOR further covenants and agrees that ASSIGNOR will communicate to the ASSIGNEE, its successors, legal representatives and assigns, any facts known to us respecting the improvements, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing and reissue applications, make all rightful oaths and generally do everything possible to aid the ASSIGNEE, its successors, legal representatives and assigns, to obtain and enforce proper patent protection for the improvements in all countries.

And ASSIGNOR further authorizes the Commissioner of Patents and Trademarks of the United States, to record the Patents and title thereto as the property of the ASSIGNEE, its successors, legal representatives and assigns in accordance with the terms of this instrument.


IN WITNESS WHEREOF, the undersigned has caused this instrument to be executed effective as of the 11<sup>th</sup> day of November, 2008 by its duly authorized officer.


  
\_\_\_\_\_  
Ole Steen Andersen  
Chairman  
\_\_\_\_\_  
Gen 416 16/11/08

PHARMEXA A/S, Assignor:

By:   
\_\_\_\_\_  
ACHIM KAUFHOLD  
Title: CEO  
Date: November 11, 2008

WITNESSED:

By:   
\_\_\_\_\_  
Dana R. Leach  
Title: SVP Business Dev. & IP  
Date: 11 November 2008

By:   
\_\_\_\_\_  
PETER HØGLUND  
Title: CEO  
Date: 16 November 2008